Table 1.
Characteristics of included studies.
| Study | Country of Origin | Population | Sample Size | Type of Sample | Region of Gene Quantification | ||
|---|---|---|---|---|---|---|---|
| Fecal Samples | Plaque Samples | Blood Samples | |||||
| Tuomisto S, 2019 [13] | Finland | CHD | 67 | √ | √ | DNA | |
| Liu HH, 2019 [14] | China | CAD | 201 | √ | V3-V4 of 16S rRNA | ||
| Emoto T, 2016 [15] | Japan | CAD | 119 | √ | 16S rDNA | ||
| Cui L, 2017 [16] | China | CHD | 64 | √ | V3-V5 of 16S rRNA | ||
| Yoshida N, 2018 [17] | Japan | CAD | 60 | √ | V3-V4 of 16S rRNA | ||
| Amar J, 2019 [18] | France | MI | 201 | √ | V3-V4 of 16S rDNA | ||
| Emoto T, 2017 [19] | Japan | CAD | 69 | √ | 16S rDNA | ||
| Toya T, 2020 [20] | USA | Advanced CAD | 106 | √ | V3-V5 of 16S rDNA | ||
| Zhu Q, 2018 [21] | China | CAD | 168 | √ | V4 of 16S rRNA | ||
| Gao J, 2020 [22] | China | ACS | 90 | √ | V4 of 16S rDNA | ||
| Zheng YY, 2020 [23] | China | CAD | 309 | √ | V3-V4 of 16S rRNA | ||
| Koren O, 2011 [11] | USA | Atherosclerosis | 30 | √ | V1-V2 of 16S rRNA | ||
| Alhmoud T, 2019 [24] | USA | ACS | 38 | √ | V3-V4 of 16S rRNA | ||
| Jie Z, 2017 [25] | China | ACVD | 405 | √ | DNA | ||
| Li CW, 2016 [26] | China | CAD | 206 | √ | 16S rRNA | ||
| Pisano E, 2019 [27] | Italy | CAD | 77 | √ | √ | 16S rRNA | |
ACS, acute coronary syndrome; ACVD, atherosclerotic cardiovascular disease; CAD, coronary artery disease; CHD, coronary heart disease; MI, myocardial infarction.